Pharmaceutical Executive-09-01-2022

A prime opportunity for pharma to raise its strategic game in ESG.

Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.

Senior leaders in pharma, healthcare marketing and communications, and advertising got together to discuss the progress and lingering roadblocks in advancing diversity, equity, and inclusion strategies in the life sciences—where the common thread seems clear: the messenger matters.

FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.

A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Launch of novel drug for rare neuromuscular disorder seeks to give voice to the patients.

Use against pair of pathways could pave way for standout in stocked eye disease market.

Tapping the potential of new market mindset in insomnia—delivering a quality next day.

Dual-targeted injection poised to rock GLP-1 field in diabetes—and eventually weight loss.

More favorable administration, reimbursement could separate latest PCSK9 entrant.

Spotlighting the stories of five noteworthy biopharma brand launches—and the diverse disorders they address with novel approaches in science and market access.

Pharm Exec catches up with longtime Merck international business leader Kevin Ali to find out how Organon, the ambitious Merck spinoff he formed just over a year ago, has fared so far in delivering on its mission of creating a global leader and difference-maker in women’s health.

Biotech stocks and the indexes have staged an impressive recovery.

What the rising rate of physician-hospital affiliations means for pharma.

How companies can adapt to today’s fast-changing hiring climate.

And, in equal measure, patients and doctors—as EU mulls new rules.

Pharm Exec releases its annual product launch feature articles.

Click the title above for a link to open the Pharmaceutical Executive September 2022 issue in an interactive PDF format.

Pharma loses battle to block price negotiations, but implementation faces many challenges.